These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 17408457)

  • 1. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.
    Hill A; Richards SJ; Hillmen P
    Br J Haematol; 2007 May; 137(3):181-92. PubMed ID: 17408457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria.
    Hill A; Rother RP; Wang X; Morris SM; Quinn-Senger K; Kelly R; Richards SJ; Bessler M; Bell L; Hillmen P; Gladwin MT
    Br J Haematol; 2010 May; 149(3):414-25. PubMed ID: 20230403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into paroxysmal nocturnal hemoglobinuria.
    Savage WJ; Brodsky RA
    Hematology; 2007 Oct; 12(5):371-6. PubMed ID: 17852463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab for paroxysmal nocturnal haemoglobinuria.
    Parker C
    Lancet; 2009 Feb; 373(9665):759-67. PubMed ID: 19144399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria].
    Villegas A; Arrizabalaga B; Bonanad S; Colado E; Gaya A; González A; Jarque I; Núñez R; Ojeda E; Orfao A; Ribera JM; Vicente V; Urbano-Ispizua Á;
    Med Clin (Barc); 2016 Mar; 146(6):278.e1-7. PubMed ID: 26895645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease.
    Schubert J; Röth A
    Eur J Haematol; 2015 Jun; 94(6):464-73. PubMed ID: 25702878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
    Hill A; Rother RP; Hillmen P
    Haematologica; 2005 Dec; 90(12 Suppl):ECR40. PubMed ID: 16464755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.
    Richards SJ; Hill A; Hillmen P
    Cytometry B Clin Cytom; 2007 Sep; 72(5):291-8. PubMed ID: 17549742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Learnings from over 25 years of PNH experience: the era of targeted complement inhibition.
    Heitlinger E
    Blood Rev; 2013 Dec; 27 Suppl 1():S1-6. PubMed ID: 24331206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
    Risitano AM
    Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
    Szer J; Hill A; Weitz IC
    Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
    Heo YA
    Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
    Varela JC; Brodsky RA
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxysmal nocturnal haemoglobinuria.
    Hill A; DeZern AE; Kinoshita T; Brodsky RA
    Nat Rev Dis Primers; 2017 May; 3():17028. PubMed ID: 28516949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow failure syndromes: paroxysmal nocturnal hemoglobinuria.
    Parker CJ
    Hematol Oncol Clin North Am; 2009 Apr; 23(2):333-46. PubMed ID: 19327587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxysmal nocturnal haemoglobinuria at Oslo University Hospital 2000-2010.
    Nissen-Meyer LS; Tjønnfjord GE; Golebiowska E; Kjeldsen-Kragh J; Akkök ÇA
    Tidsskr Nor Laegeforen; 2015 Jun; 135(11):1039-43. PubMed ID: 26080779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.